Trends and Racial Differences in the Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer

Journal of Pain and Symptom Management

Volumn 39, Issue 5, 2010, Pages 872-881

  Carson, April P ^a   Howard, Daniel L ^b   Carpenter, William R ^d   Taylor, Yhenneko J ^c   Peacock, Sharon ^f   Schenck, Anna P ^f   Godley, Paul A ^d,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Carolinas Center for Medical Excellence   (United States)

Author keywords

innovation diffusion; Prostate cancer; race ethnicity; treatment

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN;

AFRICAN AMERICAN; AGED; AGING; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER REGISTRY; CANCER REGRESSION; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; ORCHIECTOMY; PROSTATE CANCER; RACE DIFFERENCE; TUMOR DIFFERENTIATION;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; REGISTRIES; SEER PROGRAM; TIME FACTORS;

EID: 77952106519     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.09.013     Document Type: Article

References (37)

1. American Cancer Society. Cancer facts and figures (2005), American Cancer Society, Atlanta, GA
2. Stanford J.L., Stephenson R.A., Coyle L.M., et al. Prostate cancer trends 1973-1995, SEER Program. NIH Pub. No. 99-4543 (1999), National Cancer Institute, Bethesda, MD
3. Hoffman R.M., Gilliland F.D., Eley J.W., et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93 (2001) 388-395
4. Ries L.A.G., Eisner M.P., Kosary C.L., et al. SEER cancer statistics review, 1975-2002 (2005), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2002/ Accessed March 18, 2007
5. *Stat Database: Incidence-SEER 9 registries public-use (1973-2002). Surveillance Research Program (2005), Cancer Statistics Branch, National Cancer Institute, Bethesda, MD
6. Huggins C., and Hodges C.V. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
7. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
8. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
9. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 98 (2006) 839-845
10. Tolis G., Ackman D., Stellos A., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79 (1982) 1658-1662
11. Demark-Wahnefried W., Schildkraut J.M., Iselin C.E., et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 83 (1998) 320-330
12. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
13. Lu-Yao G., Moore D.F., Oleynick J., DiPaola R.S., and Yao S.-L. Use of hormonal therapy in men with metastatic prostate cancer. J Urol 176 (2006) 526-531
14. Zeliadt S.B., Potosky A.L., Penson D.F., and Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 395-402
15. Shavers V.L., Brown M., Klabunde C.N., et al. Race/ethnicity and the intensity of medical monitoring under "watchful waiting" for prostate cancer. Med Care 42 (2004) 239-250
16. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol 21 (2003) 245-254
17. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79 (1997) 235-246
18. Nair B., Wilt T., MacDonald R., and Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1 (2002) CD003506
19. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., and Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 8 Suppl IV (2002) 3-18
20. Klabunde C.N., Potosky A.L., Legler J.M., and Warren J.L. Development of a comorbidity index using physician claims data. J Clin Epidemiol 53 (2000) 1258-1267
21. Orbe J., Ferreira E., and Nunez-Anton V. Comparing proportional hazards and accelerated failure time models for survival analysis. Stat Med 21 (2002) 3493-3510
22. Shahinian V.B., Kuo Y.F., Freeman J.L., Orihuela E., and Goodwin J.S. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 (2005) 1615-1624
23. Rogers E.M. Diffusion of innovations (2003), Free Press, New York
24. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, prostate cancer, 2007. Available from http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed March 18, 2007.
25. Byar D.P. Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med 48 (1972) 751-766
26. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 (1973) 1126-1130
27. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 (2007) 1596-1605
28. Kaisary A.V., Tyrrell C.J., Peeling W.B., and Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67 (1991) 502-508
29. Peeling W.B. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33 Suppl 5 (1989) 45-52
30. Cassileth B.R., Soloway M.S., Vogelzang N.J., et al. Patients' choice of treatment in stage D prostate cancer. Urology 33 Suppl 5 (1989) 57-62
31. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 (2001) 3750-3757
32. Mariani A.J., Glover M., and Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol 165 (2001) 104-107
33. Godley P.A., Schenck A.P., Amamoo M.A., et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 95 (2003) 1702-1710
34. Klabunde C.N., Potosky A.L., Harlan L.C., and Kramer B.S. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 36 (1998) 1337-1348
35. Shavers V.L., and Brown M.L. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94 (2002) 334-357
36. Shavers V.L., Brown M.L., Klabunde C.N., et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 19 (2004) 146-155
37. Underwood III W., Jackson J., Wei J.T., et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 103 (2005) 538-545